Prognostic Impact of Preoperative the Branched-Chain Amino Acid to the Tyrosine Ratio in Hepatocellular Carcinoma Patients after Initial Hepatectomy

Journal of Gastrointestinal Surgery

Volumn 15, Issue 8, 2011, Pages 1433-1439

  Mizuguchi, Toru ^a   Kawamoto, Masaki ^a   Meguro, Makoto ^a   Nakamura, Yukio ^a   Harada, Kohei ^a   Kukita, Kazuharu ^a   Hirata, Koichi ^a  

^a SAPPORO MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

Branched chain amino acid tyrosine ratio; Hepatectomy; Hepatocellular carcinoma; Liver function

Indexed keywords

BILIRUBIN; BRANCHED CHAIN AMINO ACID; PREALBUMIN; TYROSINE;

AGED; ARTICLE; BLOOD; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; LIVER; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TUMOR; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; PREDICTIVE VALUE; PROTHROMBIN TIME; RECEIVER OPERATING CHARACTERISTIC;

AGED; AMINO ACIDS, BRANCHED-CHAIN; BILIRUBIN; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREALBUMIN; PREDICTIVE VALUE OF TESTS; PROTHROMBIN TIME; ROC CURVE; TYROSINE;

EID: 79960843029     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-011-1566-y     Document Type: Article

References (35)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
3. Schutte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma-epidemiological trends and risk factors. Dig Dis 2009; 27: 80-92.
4. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-S50.
5. Garcia-Tsao G, Lim JK. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol 2009; 104: 1802-1829.
6. Poon RT, Fan ST, Ng IO, Wong J. Significance of resection margin in hepatectomy for hepatocellular carcinoma: A critical reappraisal. Ann Surg 2000; 231: 544-551.
7. Charlton M. Branched-chain amino acid enriched supplements as therapy for liver disease. J Nutr 2006; 136: 295S-298S.
8. Tom A, Nair KS. Assessment of branched-chain amino acid status and potential for biomarkers. J Nutr 2006; 136: 324S-330S.
9. Fischer JE, Rosen HM, Ebeid AM, James JH, Keane JM, Soeters PB. The effect of normalization of plasma amino acids on hepatic encephalopathy in man. Surgery 1976; 80: 77-91.
10. Moriwaki H, Miwa Y, Tajika M, Kato M, Fukushima H, Shiraki M. Branched-chain amino acids as a protein- and energy-source in liver cirrhosis. Biochem Biophys Res Commun 2004; 313: 405-409.
11. Kvittingen EA. Hereditary tyrosinemia type I-an overview. Scand J Clin Lab Invest Suppl 1986; 184: 27-34.
12. Tanguay RM, Jorquera R, Poudrier J, St-Louis M. Tyrosine and its catabolites: from disease to cancer. Acta Biochim Pol 1996; 43: 209-216.
13. Fulenwider JT, Nordlinger BM, Faraj BA, Ivey GL, Rudman D. Deranged tyrosine metabolism in cirrhosis. Yale J Biol Med 1978; 51: 625-633.
14. Azuma Y, Maekawa M, Kuwabara Y, Nakajima T, Taniguchi K, Kanno T. Determination of branched-chain amino acids and tyrosine in serum of patients with various hepatic diseases, and its clinical usefulness. Clin Chem 1989; 35: 1399-1403.
15. Suzuki K, Koizumi K, Ichimura H, Oka S, Takada H, Kuwayama H. Measurement of serum branched-chain amino acids to tyrosine ratio level is useful in a prediction of a change of serum albumin level in chronic liver disease. Hepatol Res 2008; 38: 267-272.
16. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205-213.
17. Ninomiya T, Yoon S, Sugano M, Kumon Y, Seo Y, Shimizu K, Nagano H, Kasuga M, Hayashi Y. Improvement of molar ratio of branched-chain amino acids to tyrosine (BTR) associated with liver fibrosis in chronic hepatitis C patients treated with interferon-alpha. Dig Dis Sci 1999; 44: 1027-1033.
18. Kohashi T, Itamoto T, Katayama K, Katayama S, Hino H, Nakahara H, Tashiro H, Asahara T. Significance of the molar ratio of branched-chain amino acids to tyrosine before hepatectomy. Hepatogastroenterology 2002; 49: 774-777.
19. Kawamura-Yasui N, Kaito M, Nakagawa N, Fujita N, Ikoma J, Gabazza EC, Watanabe S, Adachi Y. Evaluating response to nutritional therapy using the branched-chain amino acid/tyrosine ratio in patients with chronic liver disease. J Clin Lab Anal 1999; 13: 31-34.
20. Rothschild MA, Oratz M, Schreiber SS. Serum albumin. Hepatology 1988; 8: 385-401.
21. Tjoeng MM, Bartelink AK, Thijs LG. Exploding the albumin myth. Pharm World Sci 1999; 21: 17-20.
22. Rondana M, Milani L, Merkel C, Caregaro L, Gatta A. Value of prealbumin plasma levels as liver test. Digestion 1987; 37: 72-78.
23. Spiekerman AM. Nutritional assessment (protein nutriture). Anal Chem 199; 67: 429R-436R.
24. Beck FK, Rosenthal TC. Prealbumin: a marker for nutritional evaluation. Am Fam Physician 2002; 65: 1575-1578.
25. Yanaga K. Current status of hepatic resection for hepatocellular carcinoma. J Gastroenterol 2004; 39: 919-926.
26. Mizuguchi T, Katsuramaki T, Nobuoka T, Kawamoto M, Oshima H, Kawasaki H, Kikuchi H, Shibata C, Hirata K. Serum hyaluronate level for predicting subclinical liver dysfunction after hepatectomy. World J Surg 2004; 28: 971-976.
27. Kaibori M, Ishizaki M, Saito T, Matsui K, Kwon AH, Kamiyama Y. Risk factors and outcome of early recurrence after resection of small hepatocellular carcinomas. Am J Surg 2009; 198: 39-45.
28. Ruzzenente A, Capra F, Pachera S, Iacono C, Piccirillo G, Lunardi M, Pistoso S, Valdegamberi A, D'Onofrio M, Guglielmi A. Is liver resection justified in advanced hepatocellular carcinoma? Results of an observational study in 464 patients. J Gastrointest Surg 2009; 13: 1313-1320.
29. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 2009; 29: 502-510.
30. Yasui M, Harada A, Torii A, Nakao A, Nonami T, Takagi H. Impaired liver function and long-term prognosis after hepatectomy for hepatocellular carcinoma. World J Surg 1995; 19: 439-443.
31. Mizuguchi T, Nagayama M, Meguro M, Shibata T, Kaji S, Nobuoka T, Kimura Y, Furuhata T, Hirata K. Prognostic impact of surgical complications and preoperative serum hepatocyte growth factor in hepatocellular carcinoma patients after initial hepatectomy. J Gastrointest Surg 2009; 13: 325-333.
32. Marchesini G, Dioguardi FS, Bianchi GP, Zoli M, Bellati G, Roffi L, Martines D, Abbiati R. Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial. The Italian Multicenter Study Group. J Hepatol 1990; 11: 92-101.
33. Fan ST, Lo CM, Lai EC, Chu KM, Liu CL, Wong J. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med 1994; 331: 1547-1552.
34. Long-term oral administration of branched chain amino acids after curative resection of hepatocellular carcinoma: a prospective randomized trial. The San-in Group of Liver Surgery. Br J Surg 1997; 84: 1525-1531.
35. Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, Loguercio C, Rossi Fanelli F, Abbiati R. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 2003; 124: 1792-1801.